Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Overview of attention for article published in The Lancet, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 58 news outlets
blogs: 6 blogs
policy: 1 policy source
twitter: 1174 X users
patent: 1 patent

facebook: 12 Facebook pages
reddit: 3 Redditors
guideline: 1 clinical guideline source
bluesky: 5 Bluesky users

Readers on

mendeley: 572 Mendeley

So far, Altmetric has seen 1331 X posts from 1174 X users, with an upper bound of 5,265,773 followers.

RT @0waki: で、「HPVワクチンの有無による発癌数の差」を見たRCTは少ない。たぶん一番有名なのがこれ。Lancet 2017。https://t.co/H643hw1Vnt 4価ワクチンと9価ワクチンを比較し、最大6年の追跡で両群とも癌は0。6年じゃそりゃ発癌しない…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1327 additional X posts.